Evidence map›Paper›PMID 35370247›Full record

ArticleInternal medicine (Tokyo, Japan)2022

Safe Concurrent Use of Anti-tuberculosis Drugs and Pembrolizumab in a Patient with Non-small-cell Lung Cancer Who Was Infected with Mycobacterium tuberculosis.

Kenji Nakahama, Hiroyasu Kaneda, Koichi Ogawa, Yoshiya Matsumoto, Yoko Tani, Tomohiro Suzumura, Shigeki Mitsuoka, Tetsuya Watanabe, Kazuhisa Asai, Tomoya Kawaguchi

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Kenji NakahamaDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Japan.
Hiroyasu KanedaDepartment of Clinical Oncology, Graduate School of Medicine, Osaka City University, Japan.
Koichi OgawaDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Japan.
Yoshiya MatsumotoDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Japan.
Yoko TaniDepartment of Clinical Oncology, Graduate School of Medicine, Osaka City University, Japan.
Tomohiro SuzumuraDepartment of Clinical Oncology, Graduate School of Medicine, Osaka City University, Japan.
Shigeki MitsuokaDepartment of Clinical Oncology, Graduate School of Medicine, Osaka City University, Japan.
Tetsuya WatanabeDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Japan.
Kazuhisa AsaiDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Japan.
Tomoya KawaguchiDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Japan.
Osaka City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 68-year-old Japanese man was diagnosed with lung adenocarcinoma stage IVB. We introduced a first-line chemotherapy of four cycles of carboplatin and pemetrexed and pembrolizumab, followed by pemetrexed and pembrolizumab maintenance therapy. Approximately four months after anticancer therapy, a small nodule appeared in the right peripheral S3 lesion. After five months, the nodule was confirmed as a Mycobacterium tuberculosis (TB) nodule. We initiated anti-TB therapy without stopping pembrolizumab, and the right S3 nodule shrank immediately. This report supports the concurrent use of anti-TB treatment with an immune checkpoint inhibitor when the TB infection area is limited.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMycobacterium tuberculosisAgedAntibodies, Monoclonal, HumanizedAntitubercular AgentsHumansMaleAntibodies, Monoclonal, HumanizedAntitubercular Agentspembrolizumabadverse eventimmune checkpoint inhibitorlung cancerpembrolizumabtuberculosis

Identifiers

PMID35370247
PMCPMC9038460
OpenAlexW4220801764

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.